This article is available to subscribers. Subscribe now. Already have an account? Sign in

PerspectiveFree Preview

Improving the Use of FDA Advisory Committees

List of authors.
  • C. Joseph Ross Daval, J.D.,
  • Aaron S. Kesselheim, M.D., J.D., M.P.H.,
  • and Ameet Sarpatwari, Ph.D., J.D.

Advisory committees cannot support public trust in FDA decisions if the agency uses them inconsistently. Simple reforms could improve accountability, transparency, and trust.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available at NEJM.org.

This article was published on August 20, 2022, at NEJM.org.

Author Affiliations

From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston.

Print Subscriber? Activate your online access.